Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facial Rhytidectomy (Face-lift)
Conditions
Facial Rhytidectomy (Face-lift)
Trial Timeline
Jun 1, 2008 → Sep 1, 2008
NCT ID
NCT00708071About Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) is a phase 2 stage product being developed by Baxter for Facial Rhytidectomy (Face-lift). The current trial status is completed. This product is registered under clinical trial identifier NCT00708071. Target conditions include Facial Rhytidectomy (Face-lift).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00708071 | Phase 2 | Completed |
Competing Products
13 competing products in Facial Rhytidectomy (Face-lift)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| Rapamune | Pfizer | Phase 1 | 32 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |